NextCell in discussions about patients with covid-19

Report this content

NextCell Pharma AB ("NextCell") announces that parallel discussions with several hospitals have been initiated to treat patients with covid-19, the severe respiratory tract infection caused by the new coronavirus, with the stem cell product ProTrans.

“We would like to emphasize that this information is preliminary. There are both administrative and regulatory challenges, but the intention from healthcare is to go forward with this. We will come back when and if further information is available, says Mathias Svahn, CEO of NextCell.

"We advise against speculative share purchases in the share due to this announcement," says Anders Essen-Möller, Chairman of the Board of NextCell.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 20th of March 2020.


For more information about NextCell Pharma AB, please contact:

Anders Essen-Möller, Chairman of the Board

Mathias Svahn, CEO

Phone: 08-735 5595







About NextCell Pharma AB:

Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell

Pharma AB develops ProTrans, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Scandinavia´s largest stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.


Documents & Links